Mapping Critical Residues in ATG11's Coiled-Coil 2 Domain that Block Multiple Interactions and Disrupt Selective Autophagy.

Selective autophagy is a conserved subcellular process that maintains the health of eukaryotic cells by targeting damaged or toxic cytoplasmic components to the vacuole/lysosome for degradation. A key player in the initiation of selective autophagy in S. Cerevisiae (baker's yeast) is a large adapter protein called Atg11. Atg11 has multiple predicted coiled-coil domains and intrinsically disordered regions, is known to dimerize, and binds and organizes other essential components of the autophagosome formation machinery, including Atg1 and Atg9. We performed systematic directed mutagenesis on the coiled-coil 2 domain of Atg11 in order to map which residues were required for its structure and function. Using yeast-2-hybrid and coimmunoprecipitation, we found only three residues to be critical: I562, Y565, and I569. Mutation of any of these, but especially Y565, could interfere with Atg11 dimerization and block its interaction with Atg1 and Atg9, thereby inactivating selective autophagy.

Covalent binding of a selective agonist irreversibly activates guinea pig coronary artery A2 adenosine receptors.

Experiments employing guinea pig heart Langendorff preparations compared the coronary vasoactivity of a functionalized congener of adenosine, 2-[(2-aminoethyl-aminocarbonylethyl)phenylethylamino]-5'-N-e thyl- carboxamidoadenosine, APEC, with the vasoactivity of the product of the reaction of APEC with 1,4-phenylene-diisothiocyanate, 4-isothiocyanatophenylaminothiocarbonyl-APEC (DITC-APEC). Previous experiments showed that whereas APEC binds reversibly to the A2A adenosine receptor of brain striatum, DITC-APEC binds irreversibly. APEC caused concentration-dependent coronary vasodilation that persisted unchanged when agonist administration continued for up to 165 min, but promptly faded when the agent was withdrawn. The unselective adenosine receptor antagonist 8-(4-sulfophenyl)theophyline (8-SPT) antagonized the vasoactivity of APEC. By contrast, DITC-APEC (0.125-1.0 nM) caused progressive, concentration-independent vasodilation that persisted unchanged for as long as 120 min after the agent was stopped and that was insensitive to antagonism by subsequently applied 8-SPT. However, perfusion of the heart with buffer containing 0.1 mM 8-SPT strongly antagonized the coronary vasodilatory action of DITC-APEC given subsequently. Such observations indicate that the covalent binding of DITC-APEC causes irreversible activation of the guinea pig coronary artery A2A adenosine receptor. Neither APEC nor DITC-APEC appeared to desensitize the coronary adenosine receptor during two or more hours of exposure to either agonist.

2-(N'-aralkylidenehydrazino)adenosines: potent and selective coronary vasodilators.

This study aimed at the development of 2-(N'-aralkylidenehydrazino)adenosines as coronary vasodilators. The reaction of aromatic aldehydes or ketones with 2-hydrazinoadenosine in refluxing methanol formed the target compounds 2-27 as crystalline products in good yields. Two kinds of receptors mediate the actions of adenosine on the heart. Retardation of impulse conduction through the atrioventricular node, the negative dromotropic action, is an example of adenosine's action at an A1 receptor (A1AR) and coronary vasodilation reflects adenosine's action at an A2 receptor (A2AR). Accordingly, bioassays employing guinea pig heart Langendorff preparations assessed the selectivity of 2-27 as coronary vasodilators. Analogues 2-27 were weak negative dromotropic agents; the EC50 of the most active analogue, 2-[N'-(1-naphthylmethylene)hydrazino]-adenosine, 23, was 0.8 microM, several orders of magnitude less than many A1AR agonists. Some of the analogues were quite active coronary vasodilators; 2-(N'-benzylidenehydrazino)adenosine, 2, and several of its para-substituted derivatives, namely, the fluoro (7), methyl (13), methoxy (16), and tert-butylcarbonylethyl, 31, had EC50s for coronary vasodilation in the range 1.7-3.2 nM. The selectivity ratios, EC50 (negative dromotropic)/EC50 (coronary vasodilatory), of these five analogues ranged between 5100 (analogue 31) and 43,000 (analogue 2). Phenyl ring substitutions of other kinds or at other positions, replacement of the phenyl ring by other aryl or heteroaryl groups, or the replacement of the benzylic H by a methyl group lowered coronary vasoactivity significantly. The unselective adenosine receptor antagonist 8-(p-sulfophenyl)theophylline raised the EC50 of the negative dromotropic activities of 2, 16, and 2-[N'-(2-naphthylmethylene)hydrazino]adenosine, 24, by 3-, 18-, and 7-fold, and raised the EC50s of coronary vasoactivity by 11-, 3-, and 30-fold, respectively evidence that vasoactivity was receptor-mediated.

2-(N'-alkylidenehydrazino)adenosines: potent and selective coronary vasodilators.

The reaction of aliphatic aldehydes and ketones with 2-hydrazinoadenosine under relatively mild conditions (at room temperature or in refluxing methanol) formed 2-(N'-alkylidenehydrazino)-adenosines, 5-22, in good yields. Two kinds of adenosine receptors regulate cardiac and coronary physiology. In supraventricular tissues an A1AR coupled to muscarinic K channels mediates the negative chronotropic, dromotropic, and inotropic actions of adenosine, and an inhibitory A1AR coupled to adenylate cyclase mediates the "antiadrenergic" action of adenosine. One or more kinds of A2 receptors mediate coronary vasodilation. Bioassays employing a guinea pig heart Langendorff preparation showed that 5-22 weakly retard impulse conduction through the AV node (negative dromotropic effect), but several analogues were very active coronary vasodilators. The coronary vasoactivity of the (n-alkylidene- and of the (isoalkylidenehydrazino)adenosines paralleled the length of the alkyl chain, the EC50s of the of the most active n-pentylidene (8) and isopentylidene (18) congeners being 1 nM. The EC50s of the cyclohexylmethylene (9), cyclohexylethylidene (10), and cyclohex-3-enylmethylene (12), analogues were likewise < 1 nM, but the cyclohex-1-enylmethylene congener 12 was 10 times less active than 9. The unselective adenosine receptor antagonist 8-(p-sulfophenyl)theophylline (0.1 mM) raised the EC50s of the negative dromotropic effects of 8, 9, and 18 by 5-28-fold and the EC50s of coronary vasodilation of 22-90-fold. Catalytic reduction of 9 increased the hydrophobicity and changed the UV spectrum, suggesting reduction of the --CH = N-- bond. The product darkened on exposure to air and so was not characterized further. A new method for preparing 2',3',5'-tri-O-acetyl-2,6-dichloropurine riboside, a precursor in the synthesis of 2-hydrazinoadenosine, consists of the addition of tert-butyl nitrite to a mixture of 2',3',5'-tri-O-acetyl-6-chloroguanosine and CuCl in CHCl3 saturated with Cl2.

Nitric oxide modulates coronary autoregulation in the guinea pig.

A guinea pig heart Langendorff preparation was used in the present study to test the hypothesis that the coronary endothelium modulates coronary autoregulation through the production of nitric oxide (NO). Pacing at 250 beats per minute and venting the left ventricle to ensure that the hearts did no external work were performed in an attempt to reduce the metabolic stimulus to coronary vasomotion and keep it constant. We measured the responses of coronary flow and oxygen metabolism to stepwise changes of the perfusion pressure over the range between 18 and 85 mm Hg. The hearts exhibited autoregulation between 25 and 55 mm Hg and active vasodilation at perfusion pressures above that range. Perfusion with 100 microM NG-nitro-L-arginine (NNLA), an inhibitor of NO synthase, decreased coronary flow over the entire range of perfusion pressures and abolished active vasodilation over 65 mm Hg, thus widening the autoregulatory range. The administration of 200 microM L-arginine, but not D-arginine, reversed the action of NNLA. Inhibition of the cyclooxygenase pathway by 10 microM indomethacin did not affect autoregulation. Perfusion with 1 nM arginine vasopressin, a direct smooth muscle constrictor, lowered coronary flow rate to the same extent as NNLA at 55 mm Hg but did not prevent the pressure-dependent increase in flow above that pressure. These observations suggest that 1) the coronary endothelium actively modulates coronary autoregulation through the production of NO but not prostanoids, 2) mechanical stress (shear stress and/or stretching secondary to vasodilation) may be the stimulus to NO production, especially above the autoregulatory range, and 3) autoregulatory tone is likely to be myogenic in origin rather than mediated by extrinsic vasoconstrictors.